Conceptio › Archive › HAL (France)
HAL (France)open access

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort

F. Cherifi et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
immunotherapy
Endocrine receptor low, Early breast, Immunotherapy, Pathological complete response, Neoadjuvant, 1, 0
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 1066303
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.